VEGFA and age-related macular degeneration: Currently, the only pharmacological treatment of AMD is the application of VEGF-A blocker—either lucentis/ranibizumabum or avastin/bevacizumab—emphasizing the necessity to understand the molecular cause of VEGF-A over-expression observed in AMD.